As pancreatic cancer overexpresses EGFR, erlotinib combined with gemcitabine was also approved for first‐line treatment for pancreatic cancer because OS was significantly longer with erlotinib plus gemcitabine than with gemcitabine (median OS: 6.24 vs. 5.91 months; HR, 0.82; 95%CI: 0.69, 0.99; p = 0.038).135. The gene discussed is EGFR; the disease is pancreatic neoplasm.